Case Report
Cutaneous and Gastrointestinal Symptoms in Two Patients with Systemic Mastocytosis Successfully Treated with Omalizumab
Table 1
Studies of mastocytosis treated with omalizumab.
| Study | Patients () | Dose | Effect |
| Systemic mastocytosis | | | | Carter et al., 2007 [7] | 2 | 300 mg/4 weeks | Patient I: no further anaphylactic episodes | Patient II: reduced gastrointestinal and anaphylactic episodes | Pitt et al., 2010 [8] | 1 | 300 mg/4 weeks | No further anaphylactic episodes | Kontou-Fili et al., 2010 [9] | 1 | 300 mg/4 weeks | No further anaphylactic episodes | Douglass et al., 2010 [10] | 1 | 150 mg/4 weeks | No further anaphylactic episodes or cardiac arrest | Paraskevopoulos et al., 2013 [11] | 1 | 300 mg/4 weeks | No further anaphylactic episodes | Kibsgaard et al., 2014 [12] | 1 | 300 mg/4 weeks | No further anaphylactic episodes | Cutaneous mastocytosis | | | | Siebenhaar et al., 2007 [13] | 1 | 150 mg/4 weeks | Reduced cutaneous symptoms | Matito et al., 2013 [14] | 1 | 450 mg/4 weeks | Reduced cutaneous symptoms | Sokol et al., 2014 [15] | 1 | 375 mg/2 weeks | Reduced cutaneous symptoms |
|
|